Baxter International, Inc. (NYSE: BAX) announced that its Phase III clinical study of immunoglobulin (IG) did not meet its co-primary ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE